The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials
暂无分享,去创建一个
Yiping Wei | Wenxiong Zhang | Qiangyun Liu | Z. Fang | Miaoweng Liu | F. Yi | Ruoxin Xu | Linxiang Zeng | Lin-Xiang Zeng